NCT05230433 is a NA clinical trial of High-fat Challenge in Pediatric Obesity, sponsored by Dartmouth-Hitchcock Medical Center.

Who is sponsoring NCT05230433?

NCT05230433 is sponsored by Dartmouth-Hitchcock Medical Center.

What drugs are being tested in NCT05230433?

Interventions in NCT05230433: High-fat Challenge.

What condition does NCT05230433 study?

NCT05230433 studies Pediatric Obesity, Insulin Resistance.

Is NCT05230433 still recruiting?

NCT05230433 is currently completed. Last updated 29 September 2025.

Are results published for NCT05230433?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2025-09-29 · How we verify

NCT05230433

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

High-fat Meal Challenge in Pediatrics

Completed NA Results posted Last updated 29 September 2025

What this trial tests

NA trial testing High-fat Challenge in Pediatric Obesity in 15 participants. Completed in 31 December 2023.

Timeline

1 May 2022

Primary endpoint
19 September 2022

31 December 2023

Quick facts

Lead sponsor	Dartmouth-Hitchcock Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	basic science
Enrollment	15
Start date	1 May 2022
Primary completion	19 September 2022
Estimated completion	31 December 2023
Sites	1 location across United States

Drugs / interventions tested

High-fat Challenge

Conditions studied

Pediatric Obesity — all drugs for Pediatric Obesity →
Insulin Resistance — all drugs for Insulin Resistance →

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

Adults 8 to 17, any sex, with Pediatric Obesity or Insulin Resistance. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Palatability of the High Fat Agent. Primary · 10 minutes

Determine the number of participants that complete at least 75% of the shake (by weight).

Group	Value	95% CI
High-fat Metabolic Challenge	13

BMI Percentile Secondary · At baseline

BMI percentile calculated for each participant. Average and standard deviations were reported.

Group	Value	95% CI
High-fat Metabolic Challenge	70	± 24

Medium Chain Acylcarnitine Concentration Secondary · 60 and 180 minutes post consumption of high fat shake

Medium chain acylcarnitines profiled in the plasma include acylcarnitine 6:0, 8:0, 10:0, 10:1, 12:0, and 12:1. Medium chain acylcarntine concentration was averaged in each participant. Average and standard deviations were reported.

Average MC acylcarnitine at 60 minutes

Group	Value	95% CI
High-fat Metabolic Challenge	0.055	± 0.015

Average MC acylcarnitine at 180 minutes

Group	Value	95% CI
High-fat Metabolic Challenge	0.061	± 0.014

Fold Change of Medium Chain Acylcarnitine at 60 and 180 Minutes. Secondary · 60 and 180 minutes post consumption of high fat shake

Group	Value	95% CI
High-fat Metabolic Challenge	0.902	± 0.021

Sponsor's own description

The objective is to determine if how physical fitness, measured using a treadmill maximal oxidative capacity test, is associated with the capacity to metabolize a high-fat meal in pediatrics (ages 8-17 years). Ability to metabolize the meal will be assessed by profiling mitochondrial and extra-mitochondrial fatty acid metabolites. The investigators will test if fatty acid oxidation mediates the relationship between fitness and markers of metabolic health, such as insulin resistance.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Pediatric Obesity

Currently open trials in the same condition.

NCT06565455 — Growing Healthy Children and Families in Rural Arkansas · NA · recruiting
NCT07342855 — Comparing Outcomes Among Children With Obesity in a Community Healthy Lifestyle Program · NA · recruiting
NCT07095166 — Monitoring Eating Across Locations (MEAL) - Timing, Intake, and Mealtime Evaluation (TIME) · NA · recruiting
NCT07229508 — Developmental Trajectories of Reinforcer Pathology and Childhood Obesity · recruiting
NCT06572345 — Low EnerGy DiEt iN Adolescents With Obesity and Type 2 Diabetes: The LEGEND Study · NA · recruiting

Other Dartmouth-Hitchcock Medical Center trials

Trials by the same sponsor.

NCT07325474 — Plan and Protect: Safety Planning for Teens in Rural Emergency Departments · NA · not yet recruiting
NCT07428629 — Piloting an Insomnia Treatment in Patients With Ulcerative Colitis · NA · not yet recruiting
NCT06777511 — Advancing Antimicrobial Photodynamic Therapy to Prevent Infection in Osseointegrated Prosthesis Patients · not yet recruiting
NCT07279116 — ABY-029 Head & Neck Trial · Phase 1 · not yet recruiting
NCT07063693 — ABY-029 Glioma Trial · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05230433 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Dartmouth-Hitchcock Medical Center
Last refreshed: 29 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05230433.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing